Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 135

1.

Targeting the chromosomal passenger complex subunit INCENP induces polyploidization, apoptosis and senescence in neuroblastoma.

Sun M, Veschi V, Bagchi S, Xu M, Mendoza A, Liu Z, Thiele CJ.

Cancer Res. 2019 Aug 15. pii: canres.0695.2019. doi: 10.1158/0008-5472.CAN-19-0695. [Epub ahead of print]

PMID:
31416840
2.

Evaluation of existing methods to extract microplastics from bivalve tissue: Adapted KOH digestion protocol improves filtration at single-digit pore size.

Thiele CJ, Hudson MD, Russell AE.

Mar Pollut Bull. 2019 May;142:384-393. doi: 10.1016/j.marpolbul.2019.03.003. Epub 2019 Apr 5.

3.

The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.

Xu N, Hua Z, Ba G, Zhang S, Liu Z, Thiele CJ, Li Z.

J Exp Clin Cancer Res. 2019 Mar 8;38(1):118. doi: 10.1186/s13046-019-1107-1.

4.

Quantitative ubiquitylome analysis and crosstalk with proteome/acetylome analysis identified novel pathways and targets of perifosine treatment in neuroblastoma.

Jiang M, Hua Z, Dong Y, Liu Z, Thiele CJ, Li Z.

Transl Cancer Res. 2018 Dec;7(6):1548-1560. doi: 10.21037/tcr.2018.11.30.

5.

P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Hua Z, Zhan Y, Zhang S, Dong Y, Jiang M, Tan F, Liu Z, Thiele CJ, Li Z.

Apoptosis. 2018 Aug;23(7-8):408-419. doi: 10.1007/s10495-018-1467-6.

6.

Identification of Casz1 as a Regulatory Protein Controlling T Helper Cell Differentiation, Inflammation, and Immunity.

Bhaskaran N, Liu Z, Saravanamuthu SS, Yan C, Hu Y, Dong L, Zelenka P, Zheng L, Bletsos V, Harris R, Harrington B, Weinberg A, Thiele CJ, Ye F, Pandiyan P.

Front Immunol. 2018 Feb 7;9:184. doi: 10.3389/fimmu.2018.00184. eCollection 2018.

7.

Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.

Souza BK, da Costa Lopez PL, Menegotto PR, Vieira IA, Kersting N, Abujamra AL, Brunetto AT, Brunetto AL, Gregianin L, de Farias CB, Thiele CJ, Roesler R.

Mol Neurobiol. 2018 Sep;55(9):7242-7258. doi: 10.1007/s12035-018-0874-6. Epub 2018 Feb 3.

PMID:
29397557
8.

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.

J Clin Invest. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4.

9.

When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

Liu Z, Thiele CJ.

Cancer Cell. 2017 Sep 11;32(3):273-275. doi: 10.1016/j.ccell.2017.08.014.

10.

High-SETD8 inactivates p53 in neuroblastoma.

Veschi V, Thiele CJ.

Oncoscience. 2017 Apr 14;4(3-4):21-22. doi: 10.18632/oncoscience.344. eCollection 2017 Mar. No abstract available.

11.

Proteome and Acetylome Analysis Identifies Novel Pathways and Targets Regulated by Perifosine in Neuroblastoma.

Gu X, Hua Z, Dong Y, Zhan Y, Zhang X, Tian W, Liu Z, Thiele CJ, Li Z.

Sci Rep. 2017 Feb 6;7:42062. doi: 10.1038/srep42062.

12.

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Veschi V, Liu Z, Voss TC, Ozbun L, Gryder B, Yan C, Hu Y, Ma A, Jin J, Mazur SJ, Lam N, Souza BK, Giannini G, Hager GL, Arrowsmith CH, Khan J, Appella E, Thiele CJ.

Cancer Cell. 2017 Jan 9;31(1):50-63. doi: 10.1016/j.ccell.2016.12.002.

13.

Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.

Odate S, Veschi V, Yan S, Lam N, Woessner R, Thiele CJ.

Clin Cancer Res. 2017 Apr 1;23(7):1771-1784. doi: 10.1158/1078-0432.CCR-16-1317. Epub 2016 Oct 19.

14.

PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma.

Hua Z, Gu X, Dong Y, Tan F, Liu Z, Thiele CJ, Li Z.

Tumour Biol. 2016 Oct 17. [Epub ahead of print]

15.

Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma.

Liu Z, Lam N, Wang E, Virden RA, Pawel B, Attiyeh EF, Maris JM, Thiele CJ.

Oncogene. 2017 Jan 5;36(1):97-109. doi: 10.1038/onc.2016.179. Epub 2016 Jun 6.

16.

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J.

Cancer Lett. 2016 Feb 28;371(2):214-24. doi: 10.1016/j.canlet.2015.11.045. Epub 2015 Dec 10.

17.

Preface: The Status of Pediatric Solid Tumors in 2015.

Thiele CJ, Helman LJ.

Crit Rev Oncog. 2015;20(3-4):v-vi. No abstract available.

18.
19.

Ascl1 phospho-status regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma.

Wylie LA, Hardwick LJ, Papkovskaia TD, Thiele CJ, Philpott A.

Dis Model Mech. 2015 May;8(5):429-41. doi: 10.1242/dmm.018630. Epub 2015 Mar 18.

20.

Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.

Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ.

Cancer Biol Ther. 2015;16(3):477-83. doi: 10.1080/15384047.2015.1016659.

Supplemental Content

Loading ...
Support Center